Please ensure Javascript is enabled for purposes of website accessibility

Why Aldeyra Therapeutics Stock Is Sinking Today

By Keith Speights - Apr 28, 2021 at 12:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company plans to conduct a public stock offering.

What happened

Shares of Aldeyra Therapeutics (ALDX -4.76%) were 8.3% lower as of 12:31 p.m. EDT on Wednesday. The decline came after the company announced plans for a $125 million public stock offering.

So what

Public offerings usually cause stocks to fall because they dilute the value of existing shares. That's why Aldeyra's share price is tumbling today. But there's a flip side to the story that's positive. These offerings enable companies to raise additional capital.

Red line with arrow trending down in front of a $100 bill

Image source: Getty Images.

Biotechs in particular tend to conduct public stock offerings after they report good news that drives share prices higher. Aldeyra announced great news on Tuesday with positive top-line results from a late-stage study evaluating reproxalap in treating allergic conjunctivitis (inflammation of the eyes caused by allergies).

The company plans to use the net proceeds from its public offering to prepare for a potential regulatory filing for reproxalap and for a commercial launch of the drug if it wins approval. Aldeyra also intends to use some of the proceeds to fund early-stage programs.

Now what

The next major move for Aldeyra is to meet with the Food and Drug Administration about submitting a New Drug Application for reproxalap. The company hopes to have this meeting in the second half of 2021. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aldeyra Therapeutics, Inc. Stock Quote
Aldeyra Therapeutics, Inc.
$3.80 (-4.76%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.